Skip to content

Formation of bilirubin photoisomers in optimalized phototherapy of neonatal jaundice.

Early Isomerization of Bilirubin in Optimized phototherapy of neonatal jaundice

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12614000716662
Acronym
Nil
Enrollment
42
Registered
2014-07-07
Start date
2009-05-28
Completion date
2012-01-18
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Bilirubin photoisomers theoretically should be less able to cross the blood-brain barrier.Therfore it is of interest to study early bilirubin izomerization during phototherapy.

Interventions

Intensified phototherapy with single fluorescent unit (one Bilicompact light) vs Double fluorescent unit (double bilicompact. light) vs phototherapy with Photodiodes (Neoblue). The neoBLUE unit emits blue LED light in the 450-470 nm with peak at 468 nm spectrum. This range corresponds to the bilirubin peak absorption wavelength of 458 nm. BiliCompact contains ten 9W,12.7-cm length fluorescent bulbs (BAM/PL9/52, Ralutec 9W/71 G 23). These bulbs have broad Gaussian emission spectra roughly fro

Intensified phototherapy with single fluorescent unit (one Bilicompact light) vs Double fluorescent unit (double bilicompact. light) vs phototherapy with Photodiodes (Neoblue). The neoBLUE unit emits blue LED light in the 450-470 nm with peak at 468 nm spectrum. This range corresponds to the bilirubin peak absorption wavelength of 458 nm. BiliCompact contains ten 9W,12.7-cm length fluorescent bulbs (BAM/PL9/52, Ralutec 9W/71 G 23). These bulbs have broad Gaussian emission spectra roughly from 400 -525 nm with a peak at 450 nm and intense mercury emission lines at 405, 436, and 546 nm Arm 1: Single phototherapy provided by one unit neoBLUE `Trademark` Arm 2: Single phototherapy with single unit BiliCompact.`Trademark`. Arm 3: Double phototherapy was administered by two units BiliCompact`Trademark`. We will take blood sample to analyse bilirubin photoisomer right befor starting phototherapy, after 30 min.60 min, 120 min Duration of phototherapy depends on the patient's response to phototherapy and how quickly falls serum total bilirbin. For this study, all children receive phototherapy at least 2-4 hours, because we are interested to see how quickly formed fotoisomerer after 15 min, 30min, 60 min, 120 min and 240 min.and 240 min. during phototherapy.

Sponsors

Faculty of Medicine, University of Oslo
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
1 Hours to 2 Weeks
Healthy volunteers
No

Inclusion criteria

Neonates with jaundice. ( Only neonate with jaundiice with BW > 1000 g)

Exclusion criteria

Premature infants < 1000 g body weight

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026